Experimental Drug Shows Promise in Protecting Nerve Cells from ALS Damage

New Hope in ALS Research: Experimental Drug Shows Promise in Protecting Nerve Cells

The ALS Ice Bucket Challenge of 2014 brought the neurodegenerative disease into the global spotlight, yet a definitive cure remains elusive. Despite continued efforts, the scientific community is still searching for effective treatments. However, a ray of hope has emerged from the University of Arizona, where researchers have identified a novel drug that holds potential in safeguarding nerve cells from ALS damage.

In a significant breakthrough, the study, detailed in Nature Aging, reveals that targeting a specific part of the TDP-43 protein could protect against nerve cell deterioration. “Current FDA-approved treatments for ALS provide only modest benefits. There is an urgent need for a real breakthrough,” stated Xinglong Wang, the senior author and a professor at the R. Ken Coit College of Pharmacy. Collaborating with Dr. Ju Gao, Wang’s team focused on this protein, which plays a crucial role in ALS.

ALS typically goes undiagnosed until significant nerve cell damage has occurred, often manifesting first as limb weakness. While genetic mutations account for fewer than 10% of cases, over 90% arise spontaneously without a known cause. Yet, a common factor in most cases is the abnormal clumping of the TDP-43 protein within nerve cells.

TDP-43 is essential for normal cell function, but in ALS, it forms toxic clumps outside the nerve cells. Previous drug development efforts aimed at dissolving these clumps have not yielded effective treatments. Unlike past attempts, the research team investigated whether a specific region of TDP-43 could be responsible for the damage, offering a new target for potential therapies.

“We asked a simple question that had never been tested: is there one specific part of TDP-43 that’s causing the harm, something a drug could switch off without disturbing the rest?” Wang explained. The team discovered a conserved region within TDP-43 that, when removed, significantly reduced nerve cell death in mice without disrupting the protein’s essential functions.

This decade-long research effort led to the development of an experimental drug, XL20, capable of targeting the identified region within the TDP-43 protein. Notably, XL20 can cross the blood-brain barrier, a major hurdle in drug delivery to the brain.

In tests on mice, XL20 extended their lifespan, reduced muscle weakness, and protected nerve cells. When applied to human motor neurons in the lab, the drug reversed some of the damage associated with ALS. Given its direct action on TDP-43 and its effectiveness in human cells, XL20 is a promising candidate for clinical trials.

Beyond ALS, the implications of this study could be far-reaching. TDP-43 abnormalities are also central to LATE, a dementia affecting many older adults, and are present in over half of Alzheimer’s cases, where they correlate with faster cognitive decline. “The same TDP-43 pathology is implicated in several other neurodegenerative diseases,” Wang noted. “If future studies show this approach works in those diseases as well, it could eventually benefit a much larger patient population.”